NanoBio Awarded Patent Covering its Novel Nanoemulsion Technology

NanoBio Corporation announced today that a sixth U.S. patent covering its novel nanoemulsion technology has been awarded. The patent encompasses composition of matter claims for the company's lead anti-infective and vaccine product candidates.

"We are very pleased with this patent award in that the new claims circumscribe all of NanoBio's anti-infective and dermatological products, as well as our intranasal and intramuscular vaccine adjuvants," said James R. Baker, Jr., MD, NanoBio's CEO and founder. "The timing of this allowance coincides nicely with several very important development milestones at NanoBio."

In December 2009, NanoBio and GlaxoSmithKline plc (GSK) announced an exclusive licensing agreement in the United States and Canada for the over-the-counter use of NB-001, NanoBio's lead product for the treatment of herpes labialis (cold sores). NanoBio is currently preparing to study the efficacy and safety of 0.3% NB-001 in two Phase 3 trials.

In addition, NanoBio's lead vaccine candidate, NB-1008, a seasonal influenza vaccine administered via a nasal dropper, has shown very promising results in a recently completed Phase 1 clinical study. The company is currently in partnership discussions with several parties regarding NB-1008.

The development of the nanoemulsion platform began in the 1990s at the University of Michigan, and has since been supported by over $110 million in grants, investments and partnership funding. The newly issued patent (U.S. #7,655,252) is licensed from the University of Michigan to NanoBio Corp. on an exclusive, worldwide basis. With this new patent, NanoBio now holds six U.S. patents and has filed over 30 additional applications.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    BlueWillow Biologics. (2019, February 14). NanoBio Awarded Patent Covering its Novel Nanoemulsion Technology. AZoNano. Retrieved on May 25, 2024 from https://www.azonano.com/news.aspx?newsID=15741.

  • MLA

    BlueWillow Biologics. "NanoBio Awarded Patent Covering its Novel Nanoemulsion Technology". AZoNano. 25 May 2024. <https://www.azonano.com/news.aspx?newsID=15741>.

  • Chicago

    BlueWillow Biologics. "NanoBio Awarded Patent Covering its Novel Nanoemulsion Technology". AZoNano. https://www.azonano.com/news.aspx?newsID=15741. (accessed May 25, 2024).

  • Harvard

    BlueWillow Biologics. 2019. NanoBio Awarded Patent Covering its Novel Nanoemulsion Technology. AZoNano, viewed 25 May 2024, https://www.azonano.com/news.aspx?newsID=15741.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.